Sarepta Therapeutics Inc
SRPT
Market Cap$12.02B
Close$
$153.22
23.1% upside
Current Fair Value
23.1% upsideUndervalued by 23.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $12.02 Billion |
|---|---|
| Enterprise Value | $11.87 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $0.18 |
| Beta | 0.66 |
| Outstanding Shares | 94,523,766 |
| Avg 30 Day Volume | 1,127,532 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 711.18 |
|---|---|
| PEG | -664.72 |
| Price to Sales | 8.89 |
| Price to Book Ratio | 12.45 |
| Enterprise Value to Revenue | 8.46 |
| Enterprise Value to EBIT | -125.12 |
| Enterprise Value to Net Income | 702 |
| Total Debt to Enterprise | 0.1 |
| Debt to Equity | 1.29 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Sarepta Therapeutics Inc
CEO: Douglas Ingram Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the...